Cage Pharma (2)

Cage Pharma is a private, preclinical-stage biotech founded in 2018, targeting the oncology market with a novel approach to disrupting cancer metabolism. The company's core strategy centers on CP-102, a compound designed to specifically inhibit tumor glycolysis, a process many cancers rely on for growth. As a preclinical entity, the company is likely funded by venture capital or grants and is preparing for its first-in-human trials. Success hinges on demonstrating clinical proof-of-concept for its metabolic inhibition approach, which could offer a new mechanism of action in oncology.

Platform focused on discovering specific inhibitors of tumor glycolysis (the Warburg effect) to disrupt cancer cell metabolism.

The field of cancer metabolism therapeutics is emerging but competitive, with several academic and biotech players investigating targets like PKM2, LDHA, and glucose transporters. Cage Pharma's differentiation will depend on the specificity, potency, and therapeutic window of CP-102 compared to these other approaches. Large pharma companies are also active in this space through internal research and partnerships.